Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit

威尔康奈尔医学 - 新泽西州罗格斯医学院临床试验单位

• 批准号: 10304140
• 负责人: ROY M. GULICK
• 金额: $ 369.44万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-10 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10304140
• 关键词: AIDS prevention; AIDS/HIV problem; Address; Affect; African American population; American; Anti-Retroviral Agents; Area; Back; Clinic; Clinical Investigator; Clinical Research; Clinical Trials Network; Clinical Trials Unit; Collaborations; Communities; Core Facility; County; Disease; Enrollment; Epidemic; Geography; Grant; HIV; HIV Infections; HIV Seroprevalence; HIV prevention trial; Health; Hepatitis; Home; Infrastructure; Island; Joints; Laboratories; Leadership; Long Island; Medicine; Mentors; National Institute of Allergy and Infectious Disease; Neighborhoods; Neurologic; New Jersey; New York City; Newly Diagnosed; Participant; Patients; Performance; Persons; Pharmacotherapy; Population Heterogeneity; Prevention Research; Prevention strategy; Prevention trial; Primary Health Care; Procedures; Records; Research; Research Personnel; Research Subjects; Research Support; Risk; Scientific Advances and Accomplishments; Seroprevalences; Shapes; Site; Therapeutic; Training; Tuberculosis; United States; Woman; Work; clinical research site; community engagement; comorbidity; cost; data quality; ethnic diversity; experience; medical schools; metropolitan; next generation; pre-exposure prophylaxis; quality assurance; racial diversity; synergism; treatment strategy; treatment trial

PROJECT SUMMARY The Weill Cornell Medicine – Rutgers New Jersey Medical School Clinical Trials Unit (WCM-NJMS CTU) will conduct National Institute of Allergy and Infectious Diseases (NIAID)-sponsored network studies of HIV treatment and HIV prevention; enroll participants from the diverse communities of the New York City (NYC)- Newark metropolitan area, the epicenter of the HIV epidemic in the U.S. -- home to 14% of Americans living with HIV; and contribute to the networks' scientific agendas. The unit consists of a central core facility and three clinical research sites (CRS). The WCM-NJMS CTU provides central research support to the three CRSs, including investigative and laboratory oversight, financial administration, quality assurance, training, and community engagement. The three CRSs, WCM-Uptown, WCM-Chelsea, and Rutgers NJMS, are located in different parts of the NYC-Newark metropolitan area and serve distinct, racially and ethnically diverse populations of people living with or at-risk for HIV. The WCM-Uptown CRS is located close to Harlem, with some neighborhoods demonstrating HIV seroprevalence rates of over 5%. The WCM-Chelsea CRS is located in Chelsea, with some neighborhoods demonstrating the highest seroprevalence rate in NYC of over 8%. The Rutgers NJMS CRS is located in the center of Newark, serving a predominately African American population with a high proportion of women, with some neighborhoods demonstrating an HIV seroprevalence rate of over 5%. WCM-NJMS CTU investigators are leaders in the field who are shaping the HIV treatment and HIV prevention research agendas. They are highly experienced with expertise in HIV cure strategies, antiretroviral drugs and treatment strategies, tuberculosis, and HIV comordibidities, including hepatitis and neurologic complications as well as HIV prevention strategies, including HIV pre-exposure prophylaxis (PrEP) and integrated strategies. Community engagement is a key strength of the WCM-NJMS CTU with both site-specific and joint Community Advisory Boards (CABs) and a strong record of effectively communicating study results back to the community. The CTU's three CRSs have successfully enrolled over 1000 participants into a wide variety of HIV treatment and prevention trials during the current grant cycle with outstanding retention and data quality. Furthermore, CTU investigators have made substantive scientific and leadership contributions to the networks. In summary, the WCM-NJMS CTU brings together a diverse group of recognized investigator leaders who will work with an experienced clinical research staff to conduct cutting-edge HIV treatment and HIV prevention studies in the NYC-Newark metropolitan areas.

项目概要 威尔康奈尔医学 - 新泽西州罗格斯医学院临床试验单位 (WCM-NJMS CTU) 将 进行国家过敏和传染病研究所 (NIAID) 赞助的艾滋病毒网络研究 治疗和艾滋病毒预防；招募来自纽约市 (NYC) 不同社区的参与者 - 纽瓦克都会区是美国艾滋病毒流行的中心，居住着 14% 的美国人 艾滋病毒；并为网络的科学议程做出贡献。 三个临床研究中心 (CRS) WCM-NJMS CTU 为这三个中心提供中央研究支持。 CRS，包括调查和实验室监督、财务管理、质量保证、培训和 三个 CRS（WCM-Uptown、WCM-Chelsea 和 Rutgers NJMS）位于 纽约市-纽瓦克大都市区的不同部分，服务于不同的种族和民族 WCM-Uptown CRS 靠近哈莱姆区，有艾滋病毒感染者或高危人群。 WCM-Chelsea CRS 位于一些社区，其 HIV 血清阳性率超过 5%。 在切尔西，一些社区的血清阳性率是纽约市最高的，超过 8%。 罗格斯大学 NJMS CRS 位于纽瓦克市中心，服务对象主要是非裔美国人 女性比例很高，一些社区的艾滋病毒血清阳性率超过 5% WCM-NJMS CTU 调查员是该领域的领导者，他们正在制定 HIV 治疗和 HIV 治疗方案。 他们在艾滋病毒治疗策略、抗逆转录病毒治疗方面拥有丰富的经验和专业知识。 药物和治疗策略、结核病和艾滋病毒合并症，包括肝炎和神经系统疾病 并发症以及 HIV 预防策略，包括 HIV 暴露前预防 (PrEP) 和 社区参与是 WCM-NJMS CTU 的一个关键优势，具有特定地点的特点。 和联合社区咨询委员会 (CAB) 以及有效沟通研究结果的良好记录 CTU 的三个 CRS 已成功招募了 1000 多名参与者。 当前拨款周期内进行的各种艾滋病毒治疗和预防试验，具有出色的保留率和数据 此外，CTU 的研究人员为该研究做出了实质性的科学和领导贡献。 总而言之，WCM-NJMS CTU 汇集了众多公认的研究人员。 领导者将与经验丰富的临床研究人员合作进行尖端的艾滋病毒治疗和 纽约-纽瓦克大都市区的艾滋病毒预防研究。